Get the Stockscreener App
4.86
0.82%
-0.04
Vanda Pharmaceuticals Inc stock is traded at $4.86, with a volume of 26,286.
It is down -0.82% in the last 24 hours and up +2.75% over the past month.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.
See More
Previous Close:
$4.90
Open:
$4.91
24h Volume:
26,286
Relative Volume:
0.04
Market Cap:
$285.42M
Revenue:
$192.64M
Net Income/Loss:
$2.51M
P/E Ratio:
18.00
EPS:
0.27
Net Cash Flow:
$12.42M
1W Performance:
-4.71%
1M Performance:
+2.75%
6M Performance:
-4.89%
1Y Performance:
+40.87%
1-Day Range:
$4.851
$4.93
1-Week Range:
$4.82
$5.12
52-Week Range:
$3.44
$6.75
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Name
Vanda Pharmaceuticals Inc
Sector
Industry
Phone
202-734-3400
Address
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VNDA | 4.86 | 285.42M | 192.64M | 2.51M | 12.42M | 0.27 |
| VRTX | 447.24 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.54 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.49 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.58 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.63 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold |
| May-12-21 | Initiated | BofA Securities | Buy |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Mar-12-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-19 | Downgrade | Citigroup | Buy → Neutral |
| Aug-01-19 | Upgrade | Citigroup | Neutral → Buy |
| Jul-25-19 | Downgrade | Stifel | Buy → Hold |
| Dec-11-18 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-04-18 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Dec-04-18 | Reiterated | Jefferies | Buy |
| Nov-08-18 | Resumed | Jefferies | Buy |
| Sep-21-18 | Resumed | Oppenheimer | Outperform |
| May-23-18 | Initiated | Citigroup | Buy |
| Jan-19-18 | Initiated | Seaport Global Securities | Buy |
| Sep-14-17 | Reiterated | Piper Jaffray | Overweight |
| Jun-27-17 | Resumed | Piper Jaffray | Overweight |
| May-26-17 | Initiated | H.C. Wainwright | Buy |
| Apr-12-17 | Initiated | Oppenheimer | Outperform |
| Nov-09-16 | Initiated | Aegis Capital | Buy |
| Oct-06-16 | Resumed | Jefferies | Buy |
View All
Vanda Pharmaceuticals Inc Stock (VNDA) Latest News
Long Term Trading Analysis for (VNDA) - Stock Traders Daily
Vanda Pharmaceuticals director sells $25,863 in stock - Investing.com India
Vanda Pharmaceuticals director sells $25,863 in stock By Investing.com - Investing.com UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
New Strong Buy Stocks For November 14th - Barchart
Vanda Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Nigeria
Vanda Pharmaceuticals to Present at Major Stifel, Jefferies Healthcare Conferences | VNDA Stock News - StockTitan
BML Capital Management LLC Sells 169,780 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com - MarketBeat
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results - Investing.com India
Earnings call: Vanda Pharmaceuticals reports mixed Q3 2024 results By Investing.com - Investing.com Australia
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2024 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Inc (VNDA) Quarterly 10-Q Report - Quartz
Vanda Seeks New Markets for Hetlioz Amid Generic Competition - Sleep Review
Vanda: Q3 Earnings Snapshot - Middletown Press
Vanda Pharmaceuticals Inc (VNDA) Q3 2024 Earnings Call Highlights: Revenue Surge Amidst Rising ... - Yahoo Finance
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Vanda Pharmaceuticals Reports Third Quarter 2024 Financial Results - PR Newswire
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Analysts Set Expectations for VNDA Q3 Earnings - MarketBeat
Vanda started at buy by H.C. Wainwright, negative enterprise value cited - MSN
Over 200% Stock UpsideVanda Pharmaceuticals Undervalued With Robust Portfolio And Pipeline: Analyst - Yahoo Finance
Brokers Issue Forecasts for VNDA FY2024 Earnings - MarketBeat
StockNews.com Begins Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) - MarketBeat
Vanda Pharmaceuticals (VNDA) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Buy Rating from Analysts at HC Wainwright - MarketBeat
VNDAVanda Pharmaceuticals Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Growth in Short Interest - MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) Coverage Initiated at StockNews.com - MarketBeat
Biotech Stock Roundup: VNDA, JAZZ Up on Updates, NVAX Suffers Setback & More - MSN
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Vanda Pharma soars as Cycle Pharma reiterates $8/share offer (update) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc.VNDA - PR Newswire
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises - Yahoo Finance
Cycle Pharmaceuticals Makes Bold Move To Acquire Vanda Pharma - Finimize
Cycle Pharmaceuticals reaffirms proposal to acquire Vanda Pharmaceuticals - Yahoo Finance
D.C. drugmaker Vanda rejects another acquisition offer - The Business Journals
Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share - BioSpace
Vanda Pharmaceuticals rejects Cycle Pharma's second takeover offer - Reuters
Vanda Pharmaceuticals Rejects Deal Proposal From Cycle Group - MarketWatch
Cycle Pharmaceuticals Stands By $488 Million Offer for Vanda - Yahoo Finance
Vanda Pharmaceuticals rejects Cycle Group's $8.00 per share bid - Investing.com
Vanda Pharmaceuticals Inc Stock (VNDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):